{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:45:01Z","timestamp":1785775501974,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12519-026-01055-0","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:11:14Z","timestamp":1782929474000},"page":"643-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"22","author":[{"given":"Bing-Li","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Rong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2083","volume":"357","author":"SB Oliveira","year":"2017","unstructured":"Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017;357:j2083. https:\/\/doi.org\/10.1136\/bmj.j2083.","journal-title":"BMJ"},{"key":"1055_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ibd.21152","volume":"16","author":"B Pigneur","year":"2010","unstructured":"Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn\u2019s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953\u201361. https:\/\/doi.org\/10.1002\/ibd.21152.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","volume":"169","author":"MJ Rosen","year":"2015","unstructured":"Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169:1053\u201360. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.1982.","journal-title":"JAMA Pediatr"},{"key":"1055_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/MIB.0000000000000003","volume":"20","author":"E Vahabnezhad","year":"2014","unstructured":"Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606\u201313. https:\/\/doi.org\/10.1097\/MIB.0000000000000003.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","volume":"143","author":"JS Hyams","year":"2012","unstructured":"Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children. Gastroenterology. 2012;143:365\u201374.e2. https:\/\/doi.org\/10.1053\/j.gastro.2012.04.046.","journal-title":"Gastroenterology"},{"key":"1055_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132:863\u201373; quiz 1165\u20136.\u00a0https:\/\/doi.org\/10.1053\/j.gastro.2006.12.003.","journal-title":"Gastroenterology"},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437\u201344. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw092.","journal-title":"J Crohns Colitis"},{"key":"1055_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","volume":"22","author":"C Olbj\u00f8rn","year":"2020","unstructured":"Olbj\u00f8rn C, Rove JB, Jahnsen J. Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: a case series and review of the literature. Paediatr Drugs. 2020;22:409\u201316. https:\/\/doi.org\/10.1007\/s40272-020-00396-1.","journal-title":"Paediatr Drugs"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:650\u201360. https:\/\/doi.org\/10.1097\/MIB.0000000000001043.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12:635\u201343. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy004.","journal-title":"J Crohns Colitis"},{"key":"1055_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/ibd\/izaa279","volume":"27","author":"D Geem","year":"2021","unstructured":"Geem D, Kugathasan S. It takes two to make it right: dual biologic and small molecule therapy for treatment-refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1361\u20132. https:\/\/doi.org\/10.1093\/ibd\/izaa279.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ibd.20014","volume":"13","author":"BE Sands","year":"2007","unstructured":"Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13:2\u201311. https:\/\/doi.org\/10.1002\/ibd.20014.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR13","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:e361\u201379. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ibd\/izaf188","volume":"32","author":"SR Anderson","year":"2026","unstructured":"Anderson SR, Osman A, Zamani M, Alayo Q, Yarur AJ, Thomas D, et al. Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel diseases. Inflamm Bowel Dis. 2026;32:39\u201352. https:\/\/doi.org\/10.1093\/ibd\/izaf188.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1055_CR16","volume-title":"Development of a quality appraisal tool for case series studies using a modified delphi technique","author":"C Moga","year":"2012","unstructured":"Moga C, Guo B, Schopflocher D, Harstall C. Development of a quality appraisal tool for case series studies using a modified delphi technique. Edmonton, AB: Institute of Health Economics; 2012."},{"key":"1055_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"key":"1055_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3760\/cma.j.issn.1673-4912.2024.08.009","volume":"31","author":"T-L Mei","year":"2024","unstructured":"Mei T-L, Guo S, Li J, Guan D-X, Ye X-L, Wu J. Analysis of ten cases of refractory inflammatory bowel disease in children treated with dual targeted therapy. Chin Pediatr Emerg Med. 2024;31:602\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.1673-4912.2024.08.009\u00a0(in Chinese).","journal-title":"Chin Pediatr Emerg Med"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jpn3.12179","volume":"79","author":"M Wlazlo","year":"2024","unstructured":"Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Matuszczyk M, Kierkus J. Combination biologic therapy in pediatric inflammatory bowel disease: safety and efficacy over a minimum 12-month follow-up period. J Pediatr Gastroenterol Nutr. 2024;79:54\u201361. https:\/\/doi.org\/10.1002\/jpn3.12179.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1055_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","volume":"27","author":"MT Dolinger","year":"2021","unstructured":"Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1210\u20134. https:\/\/doi.org\/10.1093\/ibd\/izaa277.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/children12010075","volume":"12","author":"C Guo","year":"2025","unstructured":"Guo C, Zhou J, Wang G, Wu J. Dual biologic or small molecule therapy in pediatric inflammatory bowel disease: a single center experience. Children. 2025;12:75. https:\/\/doi.org\/10.3390\/children12010075.","journal-title":"Children"},{"key":"1055_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/ibd\/izad064","volume":"30","author":"A Yerushalmy-Feler","year":"2024","unstructured":"Yerushalmy-Feler A, Olbjorn C, Kolho KL, Aloi M, Musto F, Martin-de-Carpi J, et al. Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the Pediatric IBD Porto Group of ESPGHAN. Inflamm Bowel Dis. 2024;30:159\u201366. https:\/\/doi.org\/10.1093\/ibd\/izad064.","journal-title":"Inflamm Bowel Dis"},{"key":"1055_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/children10010011","volume":"10","author":"M Wlaz\u0142o","year":"2022","unstructured":"Wlaz\u0142o M, Meglicka M, Wiernicka A, Osiecki M, Kierku\u015b J. Dual biologic therapy in moderate to severe pediatric inflammatory bowel disease: a retrospective study. Children. 2022;10:11. https:\/\/doi.org\/10.3390\/children10010011.","journal-title":"Children"},{"key":"1055_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MEG.0000000000002203","volume":"34","author":"G Howard","year":"2022","unstructured":"Howard G, Weiner D, Bar-Or I, Levine A. Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn\u2019s disease in children. Eur J Gastroenterol Hepatol. 2022;34:372\u20134. https:\/\/doi.org\/10.1097\/MEG.0000000000002203.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl 3","key":"1055_CR25","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1053\/j.gastro.2019.11.275","volume":"158","author":"A Goyal","year":"2020","unstructured":"Goyal A, Bass J. P090 safety and efficacy of combining biologicals in children with inflammatory bowel disease. Gastroenterology. 2020;158(Suppl 3):S122\u20133. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.275.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"1055_CR26","doi-asserted-by":"publisher","first-page":"i372","DOI":"10.1093\/ecco-jcc\/jjab232.496","volume":"16","author":"M Wlaz\u0142o","year":"2022","unstructured":"Wlaz\u0142o M, Jarz\u0119bicka D, Meglicka M, Kierku\u015b J. P369 dual biologic in moderate to severe pediatric inflammatory bowel disease: a case series. J Crohns Colitis. 2022;16(Suppl 1):i372\u20133. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab232.496.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"1055_CR27","doi-asserted-by":"publisher","first-page":"i747","DOI":"10.1093\/ecco-jcc\/jjac190.0747","volume":"17","author":"R Abbas","year":"2023","unstructured":"Abbas R, Ibrahim N, Elawad M, Al-Mudahka F, Abdelrhman H, Akobeng AK. P617 dual biologic therapy in pediatric inflammatory bowel disease. J Crohns Colitis. 2023;17(Suppl 1):i747\u20138. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0747.","journal-title":"J Crohns Colitis"},{"key":"1055_CR28","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1007\/s10620-024-08379-9","volume":"69","author":"A Kellar","year":"2024","unstructured":"Kellar A, Dolinger MT, Spencer EA, Dubinsky MC. Real-world outcomes of dual advanced therapy in children and young adults with inflammatory bowel disease. Dig Dis Sci. 2024;69:1826\u201333. https:\/\/doi.org\/10.1007\/s10620-024-08379-9.","journal-title":"Dig Dis Sci"},{"key":"1055_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241309871","volume":"18","author":"A Fabisiak","year":"2025","unstructured":"Fabisiak A, Caban M, Dudek P, Strig\u00e1\u010d A, Ma\u0142ecka-Wojciesko E, Talar-Wojnarowska R. Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions. Ther Adv Gastroenterol. 2025;18:17562848241309871. https:\/\/doi.org\/10.1177\/17562848241309871.","journal-title":"Ther Adv Gastroenterol"},{"key":"1055_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf161","volume":"19","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Chaparro M. Combination therapy with biologics and\/or small molecules in inflammatory bowel disease: a comprehensive review. J Crohns Colitis. 2025;19:jjaf161. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf161.","journal-title":"J Crohns Colitis"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-026-01055-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:52:50Z","timestamp":1785772370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-026-01055-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s12519-026-01055-0","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. The authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}